ABT 165

Drug Profile

ABT 165

Alternative Names: ABT-165

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AbbVie
  • Class Antineoplastics; Immunoglobulins
  • Mechanism of Action DLL4 protein inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I Solid tumours

Most Recent Events

  • 19 Feb 2018 Phase-II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, In adults, In the elderly, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03368859)
  • 19 Dec 2017 ABT 165 is still in phase I trials for Solid tumours in USA (Abbvie pipeline, December 2017)
  • 11 Dec 2017 AbbVie plans a phase II trial for Colorectal Cancer (Late-stage disease, Second-line therapy or greater, In adults, In the elderly, Metastatic disease, Combination therapy) in USA in January 2018 (IV) , (NCT03368859)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top